Celaid Therapeutics Completes Second Close of Series B Financing Round
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 5, 2026 /PRNewswire/ — Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the completion of the second close of its Series B financing round. The round welcomed […]





